Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Technology Stocks : NASI (North American Scientific, Inc. -- Ignore unavailable to you. Want to Upgrade?

To: richard houchin who wrote (463)	3/3/1998 2:31:00 AM
From: Michael Paul Langley	Respond to of 658

Richard, thank you for your informative response as it was very helpful in gathering info on Nasi. Revenue and earning projections by M.H. Meyerson are indeed impressive in the upcoming fiscal years (it will be interesting to see how close their projections actually are to reality in the coming years). Is Nasi going to use both palladium and iodine isotopes in the treatment of prostate cancer. I congratulate you on finding Nasi in 1990 when it was in its infancy (I'm sure back then it was quite the speculative investment). I just wish I had bought in the beginning of 1997 before the stock price took off in earnest. I hope to add Nasi to my favorite stocks in the near future by buying on any weakness if possible. Thanks again for taking the time to respond to my request.

To: richard houchin who wrote (463)	3/5/1998 8:57:00 PM
From: mlt	Respond to of 658

i thought nasi was only into 125 I seeds , where is the info that they are going into the palladium seed business. this is very interesting and quite promising as theragenics is the only palladium seed source at this time. tell me more if you know

To: richard houchin who wrote (463)	3/6/1998 2:39:00 AM
From: Michael Paul Langley	Respond to of 658

M.H. Meyerson's research report appears to be very aggressive in their numbers predicted compared to CIBC Oppenheimer whose analyst (Only 1 analyst follows NASI) predicts $.30 a share for fiscal 98 and $1.21 in fiscal 99. Even if NASI's numbers fall on the low side it is still great earning growth from $.08 in fiscal 97. (If Oppenheimers #'s occur 175% growth in 98 and another 203% earning growth for 99). I will continue to watch NASI in great interest.